Zomedica Pharmaceuticals Corp. (ZOM)
Stock Price:
$0.168 USD
-0.057 (-25.20%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
52.66M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-10.56M |
| Shares Out |
292.02M |
| EPS (ttm) |
-0.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$0.168 |
| Previous Close |
$0.225 |
| Change ($) |
-0.057 |
| Change (%) |
-25.20% |
| Day's Open |
0.160 |
| Day's Range |
0.155 - 0.180 |
| Day's Volume |
287,550,278 |
| 52-Week Range |
0.110 - 0.499 |
More Stats
| Market Cap |
52.66M |
| Enterprise Value |
52.67M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
292.02M |
| Float |
137.88M |
| EPS (basic) |
-0.1 |
| EPS (diluted) |
-0.10 |
| FCF / Share |
-0.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.15M |
| Short Ratio |
0.15 |
| Short % of Float |
2.99% |
| Beta |
0.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
12.42 |
| Revenue |
n/a |
| Operating Income |
-10.49M |
| Net Income |
-10.56M |
| Free Cash Flow |
-15.46M |
| Net Cash |
-7,167 |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-119.25% |
| ROE |
-29,421.11% |
| ROIC |
-550.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
0.50
Current: 0.168
High
0.50
Target: 0.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -19.79 | -16.65 | -8.08 | -5.73 |
| Net Income | -19.78 | -16.65 | -8.07 | -5.74 |
| Shares Outstanding | 106 | 93.44 | 87.40 | 80.16 |
| Earnings Per Share | -0.19 | -0.18 | -0.09 | -0.07 |
| Operating Cash Flow | -15.63 | -11.15 | -7.09 | -4.56 |
| Capital Expenditures | -0.16 | -0.62 | -0.17 | -0.23 |
| Free Cash Flow | -15.79 | -11.77 | -7.26 | -4.79 |
| Cash & Equivalents | 0.51 | 1.94 | 3.45 | 3.23 |
| Total Debt | - | - | - | 0.01 |
| Net Cash / Debt | 0.51 | 1.94 | 3.45 | 3.22 |
| Assets | 4.18 | 6.03 | 5.22 | 4.58 |
| Liabilities | 2.09 | 2.38 | 0.83 | 0.74 |
| Book Value | 2.10 | 3.66 | 4.39 | 3.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zomedica Pharmaceuticals Corp. |
| Country |
United States |
| Employees |
28 |
| CEO |
Robert Cohen |
Stock Information
| Ticker Symbol |
ZOM |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NYSEAMERICAN: ZOM |
Description
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.